Introduction: Antiphospholidsyndrome (APS) is an autoimmune hypercoagulablestate caused by antiphospholid antibodies. Primary antiphospholipidsyndrome occurs in absence of any other related disease. Secondary antiphospholipid syndrome occurs with other autoimmune disease as systemic lupus erythrematosis. The clinical features of the APS are various, but the most common clinical presentation is pregnancy loss, DVT. Pulmonary thromboembolism, the cardiac manifestations of APS include myocardial infarction, pericardial effusion, myocardiopathy, and coronary artery thrombosis, but the most common manifestation is valvular abnormalities. Aim: to investigate the influence of obesity in women diagnosed as an antiphospholipid cases according to Sydney's criteria on pregnancy morbidities, vascular events, pulmonary thromboemboism and laboratory criteria. Methods: A case control study was conducted that include women attending obstetric outpatient clinic. These women were previously diagnosed as antiphospholipid cases according to (Sydney's criteria).A total of 60 women have been equally divided into two groups: First group corresponds to control group which includes 30 women with normal body mass index (BMI) i.e. < 30 Kg/m2 and, second group include 30 obese women with (BMI > 30Kg/m2). Results: Obesity is independent predictor for preterm birth intrauterine fetal death and pulmonary thromboembolism.
INTRODUCTION
The antiphospholipid syndrome (APS) is an autoimmune disease characterize by arterial and venous thrombosis due to antiphospholipid antibodies. The disorder is referred to as primary when it occurs in the absence of another autoimmune disease. Secondary APS occurs in the context of an autoimmune disorder such as systemic lupus erythematosus. The catastrophic APS (CAPS) is a rare life-threatening form of APS in which widespread intravascular thrombosis results in multiorgan ischemia and failure (Cervera et al., 2009 ; Nayer and Ortega, 2014) .
The other major clinical manifestations of the antiphospholipid syndrome are obstetrical. They include the unexplained death of one or more morphologically normal fetuses at or beyond the 10th week of gestation, the premature birth of one or more morphologically normal fetuses before the 34th week of gestation because of either eclampsia or severe preeclampsia, and three or more unexplained, consecutive spontaneous abortion before the10thweek of gestation (Lochshin et al.,2006; Giannakopoulos and Krilis,2013) .
These Cases with poor obstetric outcome are known to have obstetric antiphospholipid syndrome (OAPS) (Alijotas-Reig et al., 2012; Alijotas-Reig et al.,2014) .
The clinical features of the APS are various, but the most common clinical presentation is pregnancy loss, deep venous thrombosis (DVT) Ye et al., 2005) . Pulmonary thromboembolism, the cardiac manifestations of APS included (myocardial infarction, pericardial effusion, myocardiopathy, and coronary artery thrombosis, but the most common manifestation is valvular abnormalities) (Espisonsa et al., 2002; Ye et al.,2005) .
AIM OF THE WORK
The aim of the current study is to investigate the influence of obesity in women diagnosed as having antiphospholipid syndrome (according to Sydney's criteria) on pregnancy morbidities, vascular events, and pulmonarythromboemboism and laboratory criteria.
PATIENTS AND METHODS
A case control study was conducted that include women attending obstetric outpatient clinic. These women were previously diagnosed as antiphospholipid cases according to (Sydney's criteria).
Due to scarcity of antiphosphoipid cases, women participating in this current study were collected from outpatient clinic of three hospitals, Boulak El Dakror General Hospital, Embaba General Hospital and Om Elmasrein GeneralHospital.
The period of the study was about 24 months from august 2015 till August 2017.
Thrombotic events both venous and arterial of every patient were analyzed, pregnancy morbidities included in Sydney's classification were evaluated also laboratory investigations included in Sydney's criteria were examined and then among 200 patient with antiphospholipid syndrome attending the outpatient clinics of the three hospitals, 60 patients were selected to participate in this study.
A written consent to take part in the study was obtained. Refusal to participate in the study was an obvious exclusion criteria.
Inclusion Criteria: Women who were previously diagnosed as having antiphospholipid syndrome as described by Sydney's criteria.
According to Sydeny's criteria; APS is diagnosed when at least one of the following clinical criteria and one of the following laboratory criteria are met.
Laboratory Criteria:
1) Lupus anticoagulant (LA) present in plasma, on two or more occasions at least 12 weeks apart, detected according to the guidelines of the International Society on Thrombosis and Haemostasis.
2) Anticardiolipin (aCL) antibody of IgG and/or IgMisotype in serum or plasma, present in medium or high titer, on two or more occasions, at least 12 weeks apart, measured by standardized ELISA.
3) Anti 2glycoprotein-1 antibody of IgG and/or IgMisotype in serum or plasma (in titer >99th percentile), present on two or more occasions, at least 12 weeks apart, measured by standardized ELISA (Marchetti et al.,2013) .
Clinical Criteria:
1) 1 unexplained fetal deaths ≥10 weeks of gestation with normal anatomy by prenatal ultrasound examination or direct postnatalexamination.
2) ≥1 preterm deliveries of a morphologically normal infant before 34 weeks of gestation due to severe preeclampsia, eclampsia, or features consistent with placentalinsufficiency.
3) ≥3 unexplained, consecutive, spontaneous pregnancy losses <10 weeks of gestation, after exclusion of maternal anatomic and hormonal abnormalities and paternal and maternal chromosomal abnormalities (Charles & Michael, 2017) .
Exclusion Criteria:
 Women who didn't have obstetric morbidities or have obstetric morbidities but were not as described in Sydney's criteria.  The resultant data was tabulated and statistical analysis wasdone.
STATISTICAL METHODS
Data were analyzed using SPSS© Statistics version 23 (IBM© Corp., Armonk, NY, USA).
Categorical variables were presented as number and percentage and between-group differences were compared using Fisher's exact test.
Normality of numerical data distribution was examined using the Shapiro-Wilk test. Normally distributed numerical variables were presented as mean ± SD and inter-group differences were compared using one-way analysis of variance (ANOVA) with application of the Tukey-Kramer test for multiple Pairwise comparisons if there was a statistically significant difference among thegroups.
Multivariable binary logistic regression analysis was used to examine the relation between obesity and individual disease manifestations or outcomes as adjusted for other confoundingfactors.
Two-sided p-value <0.05 was considered statistically significant. After adjustment for other variables, younger age (odds ratio = 0.865, 95% CI = 0.780 to 0.959, p-value = 0.006), obesity (odds ratio = 5.998, 95% CI = 1.345 to 26.752, p-value = 0.019) was independent predictors for PMB. After adjustment for other variables, older age (odds ratio = 1.137, 95% CI = 1.022 to 1.264, p-value = 0.018), obesity (odds ratio = 10.087, 95% CI = 1.712 to 59.448, p-value = 0.011) was independent predictors for IUFD. After adjustment for other variables, older age (odds ratio = 1.283, 95% CI = 1.107 to 1.487, p-value = 0.001), obesity (odds ratio = 40.690, 95% CI = 3.057 to 541.690, p-value = 0.005 was independent predictors for PTE. After adjustment for other variables, obesity was not an independent predictor for vascular events (all p-values >0.05). After adjustment for other variables, obesity was not an independent predictor for a positive LAC test (all p-values >0.05). After adjustment for other variables, obesity was not an independent predictor for a positive aCLIgG test (all p-values >0.05). After adjustment for other variables, obesity was not an independent predictor for a positive aCLIgM test (all p-values >0.05). After adjustment for other variables, obesity was not an independent predictor for a positive anti B2glycoprotien -1, IgG and/or IgM (all p-values >0.05).
RESULTS

DISCUSSION
A major cause of morbidity and mortality of the antiphospholipid syndrome (APS) is the occurrence of thrombotic events (Felipe et al., 2014) .
Obesity is an established risk factor for thrombosis; it is related with adverse pregnancy outcome. Coexistence of obesity with antiphospholipid syndrome (APS) raises the risk of developing thrombosis. (Cedergren, 2004) . This current study evaluate the impact of obesity as a risk factor of (APS) by comparing incidence of pregnancy morbidities (REM, PMB-IUFD), PTE, vascular events and presence of:  Anti-cardiolipinIgG and/or IgM measured by standardized non cofactor dependent ELISA on 2 or more occasions, not less than 12 weeks a part: medium or high titre (i.e> the 99thpercentile).
 Lupus anticoagulant detected on 2 occasions not less than12 weeks a part according to the guidelines of international society of thrombosis andhemostasis.
Anti-B2 glycoprotein-1 IgG and/or IgMisotype in serum or plasma in titre> the 9th percentile) present on two occasions at least twelve weeks apart measured by a standardized ELISA.
In two groups of women who were previously diagnosed as (APS) cases according to Sydney's criteria.
 First group consists of 30 patients who have normal(BMI) <30. This group is considered as control group (reference group).
 Second group consists of 30 patients who have (BMI) > 30Kg/m2. Table 1 describes the relation between obesity and presentation of the disease. The table shows that there is no statistically significant difference in age between obese group and no obese group (P value 0.53) (the obese group).
But there is significant difference in duration of disease between the previous two groups p value 0.022. This result disagree with Caldas et al. (2010) who reported that there is no significant difference in age and duration of the disease between obese and non obese group P value is 0.78 and 0.78. Caldas et al. (2010) who reported that obese group had a higher frequency of obstetric event 53.3% than non obese group 22.8% p value 0.04. El-Bokary, et al Vol.42, No.1, jun. 2018 73 This table also shows that there is no significant difference in the incidence PTE between obese and non obese group 43.3% and 28.3%
respectively P value is 0.165. This result disagree with Caldas et al. (2010) who reported that there is significant difference in the incidence of PTE between obese and non obese group 96.6% and 14.2% respectively p value is 0.022.
In case of vascular event table (1) show that there is no significant difference between obese and non obese group 30% in both groups p value.
This agree with Caldas et al. (2010) show reported that there is no significant difference in vascular event between obese and non obesegroup.
The result of laboratory characteristics of (APS) patients obese and non obese show that LAC was more frequent in non obese (APS) patients than obese are 86.7% in non obese group and 53.3% in obese group Pvalue 0.001. On other hand there is no significant difference between obese and non obese group in other laboratory criteria. This result agree with Caldas et al. (2010) who reported that the incidence of LAC in non obese group (94.2%) is higher than obese group (53.340) P value is 0.01 and there is no significant difference between obese group and non obese group in other laboratory criteria (Caldas et al. (2010) explained this finding by comparing with some data from previous literature that show a lower prevalence of antinuclear antibodies in women with overweight or obesity (Conzalez et al., 2008) , being speculated the role of leptin resistance in obese individuals, could impair antinuclear antibodies production by B lymphocytes (Brito et al.,2006) .
A multivariable binary logistic regression analysis for relation between obesity and criteria of the disease was done and showed the following data: Table 2 : as regard REM: Obesity was not an independent predictor factor for REM. On the other hand age was independent predictor for PTB odd ratio = 0.65, 95%, CI= 0.780 to 0.959 p value 0.006. This agree with Hediger et al. (1997) who reported that after adjusting for all risk factors young adolescent overall had a nearly 75% increased risk of PMB (adjusted odds ratio -1.74) (95C3 1.07-2.84). et al. (2014) who reported that in analysis of BMI at delivery women with BMI of 25 to 29 showed higher prevalence than women with BMI greater than 30 (7 vs 5 cases).
Older age was independent predictor for PTE odd ratio = 1.2833 95%
(CI= 1.107-1.487) P value 0.001 this agree with Min et al. (2014) who reported that the prevalence of pregnancy associated pulmonary embolism (PAPE) was high in advanced maternal age(46.2%). Table 6 as regard vascular event: This study showed that obesity was not an independent predictor for vascular events (p value > 0.05). This disagrees with Klovaite et al. (2015) who reported that risk of DVT increased with increasing BMI (P Trend < 0.001). This disagrees with Caldas et al. (2010) who reported that LAC was more frequent in non-obese primary antiphospholipid patients (PAPs) patient than obese ones P value <0.01.
RECOMMENDATIONS
Patient with APS need to take all possible measures to lower the risk of developing blood clots. This includes: maintaining a healthy body weight, no smoking and remaining physically active.
